Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 8/20 | 0.71 |
| ▸ | P4HTM | Q9NXG6 | 11/20 | 0.71 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249813 | 0.86 | VHL (0.69) | VHLP4HTMEGLN1 | |
| SCHEMBL3620822 | 0.85 | P4HTM (0.67) | VHLP4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL3612340 | 0.84 | P4HTM (0.66) | VHLP4HTMEGLN1 | |
| SCHEMBL8186022 | 0.84 | VHL (0.71) | VHLP4HTMEGLN1CYP2A6 | |
| SCHEMBL8257398 | 0.83 | VHL (1.00) | VHLP4HTMEGLN1 | |
| SCHEMBL3588274 | 0.83 | VHL (0.69) | VHLP4HTMEGLN1 | |
| SCHEMBL8195371 | 0.83 | P4HTM (0.71) | VHLP4HTMEGLN1 | |
| SCHEMBL8203416 | 0.83 | P4HTM (1.00) | VHLP4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL3617381 | 0.83 | VHL (0.70) | VHLP4HTMEGLN1CYP2A6 | |
| SCHEMBL8254689 | 0.83 | VHL (0.72) | VHLP4HTMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085572-B2 | 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252817-B2 | Dipyridyl-dihydropyrazolones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | BAYER HEALTHCARE AG (DE) | 2010-02-11 | — | — | US | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1877396-B1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1877396-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | Bayer HealthCare AG (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114213-A1 | 4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322772-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | PPIP5K2, THPO, DPYD | VHL 35/4885P4HTM 657/4885EGLN1 1855/4885 |
| US-20100035906-A1 | Dipyridyl-dihydropyrazolones and their use | DPP7, DPP4, QDPR | VHL 38/4885P4HTM 633/4885EGLN1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.